{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-22-000004","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2022-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.105927+00:00","generated_at":"2026-06-27T11:19:48.325022+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Regeneron Q4 revenue surges 104% to $4.95B; REGEN-COV writedown $232M","bullets":["Q4 GAAP diluted EPS $19.69 vs $10.24; non-GAAP EPS $23.72 vs $9.53.","EYLEA U.S. net sales $1.55B (+15% YoY); full year $5.79B (+17%).","$232M writedown of REGEN-COV inventory due to Omicron; EUA revised to exclude Omicron regions.","FY2022 non-GAAP guidance: R&D $2.8B-$3.0B; SG&A $1.65B-$1.77B; gross margin 90-92%.","Board authorized $3B share repurchase program."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-22-000004","json":"https://secwatch.observer/filing/0001804220-22-000004.json","markdown":"https://secwatch.observer/filing/0001804220-22-000004.md","text":"https://secwatch.observer/filing/0001804220-22-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000004/0001804220-22-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000004/regn-20220204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T11:19:48.325022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}